Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease
- PMID: 12559940
- DOI: 10.1016/s0195-668x(02)00312-3
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease
Abstract
Aim: Unstable coronary artery disease (CAD) is a multifactorial disease involving both thrombotic and inflammatory processes. We have assessed the time-course and the influence of thrombin inhibitors on changes in fibrinogen and C-reactive protein levels, and their relation to myocardial ischaemia in unstable CAD.
Methods and results: Three hundred and twenty patients were randomized to 72 h infusion with three different doses of inogatran, a direct thrombin inhibitor, or unfractionated heparin. There were no significant differences between the treatment groups in fibrinogen or C-reactive protein levels. Overall, the fibrinogen levels were significantly increased in the first 24-96 h and still elevated at 30 days. The C-reactive protein levels showed a more pronounced increase during the first 24-96 h, but then markedly decreased over 30 days. Troponin-positive compared to troponin-negative patients had higher fibrinogen and C-reactive protein levels up to 96 h, although there was an increase compared to pre-treatment levels in both groups. A high fibrinogen level (pre-treatment top tertile) was associated with an increased rate of death or myocardial (re-)infarction at 30 days, 13% vs 5.6%, P=0.03, and increased long-term mortality. A high C-reactive protein level was related to increased 30-day mortality, 4% vs 0%, P=0.01.
Conclusion: Myocardial cell injury was related to a high degree of inflammation, only some of which is an acutephase response due to tissue damage. The rise in fibrinogen was sustained, which might reflect low grade inflammation with long-term risk of thrombosis. The transient elevation of C-reactive protein levels might indicate a propensity to a pronounced inflammatory response and is associated with increased mortality.
Comment in
-
Cardiac markers in acute coronary syndromes-refining our knowledge.Eur Heart J. 2003 Jan;24(2):136-7. doi: 10.1016/s0195-668x(02)00798-4. Eur Heart J. 2003. PMID: 12573270 No abstract available.
Similar articles
-
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.Eur Heart J. 1999 Nov;20(22):1657-66. doi: 10.1053/euhj.1999.1750. Eur Heart J. 1999. PMID: 10543929 Clinical Trial.
-
A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin inhibition in Myocardial Ischaemia (TRIM) study group.Eur Heart J. 1997 Sep;18(9):1416-25. doi: 10.1093/oxfordjournals.eurheartj.a015467. Eur Heart J. 1997. PMID: 9458447 Clinical Trial.
-
The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.Eur Heart J. 1999 Apr;20(7):506-18. doi: 10.1053/euhj.1998.1336. Eur Heart J. 1999. PMID: 10365287 Clinical Trial.
-
Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.Thromb Haemost. 2004 Feb;91(2):381-7. doi: 10.1160/TH03-07-0427. Thromb Haemost. 2004. PMID: 14961168 Clinical Trial.
-
Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.N Engl J Med. 2000 Oct 19;343(16):1139-47. doi: 10.1056/NEJM200010193431602. N Engl J Med. 2000. PMID: 11036119 Clinical Trial.
Cited by
-
Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction.Exp Ther Med. 2017 Nov;14(5):4942-4950. doi: 10.3892/etm.2017.5175. Epub 2017 Sep 21. Exp Ther Med. 2017. PMID: 29201198 Free PMC article.
-
Positive cooperativity between the thrombin and bradykinin B2 receptors enhances arachidonic acid release.Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H948-58. doi: 10.1152/ajpheart.00868.2005. Epub 2005 Sep 23. Am J Physiol Heart Circ Physiol. 2006. PMID: 16183725 Free PMC article.
-
Simultaneous non-negative matrix factorization for multiple large scale gene expression datasets in toxicology.PLoS One. 2012;7(12):e48238. doi: 10.1371/journal.pone.0048238. Epub 2012 Dec 14. PLoS One. 2012. PMID: 23272042 Free PMC article.
-
Estimated Glomerular Filtration Rate in Short-Risk Stratification in Acute Myocardial Infarction.Cardiorenal Med. 2011;1(2):131-138. doi: 10.1159/000327021. Epub 2011 Apr 15. Cardiorenal Med. 2011. PMID: 22258400 Free PMC article.
-
Myocardial ischaemia and the inflammatory response: release of heat shock protein 70 after myocardial infarction.Heart. 2005 Mar;91(3):299-304. doi: 10.1136/hrt.2003.028092. Heart. 2005. PMID: 15710705 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous